Class Action Lawsuit Filed Against ImmunityBio Following FDA Warning and Stock Drop
A class action lawsuit has been filed against ImmunityBio (NASDAQ: IBRX) following an FDA warning letter over misleading promotions of its drug Anktiva. The stock dropped 21.12% on March 24, 2026, after the public disclosure of the FDA's concerns.
Tickers: $IBRX